about
PTPN22 R620W Polymorphism is Associated with Myasthenia Gravis Risk: A Systematic Review and Meta-AnalysisDeterminants of quality of life in Brazilian patients with myasthenia gravis.The MG composite: an outcome measure for myasthenia gravis for use in clinical trials and everyday practice.Preoperative high-dose steroid has long-term beneficial effects for myasthenia gravis.Social disadvantages associated with myasthenia gravis and its treatment: a multicentre cross-sectional study.Recommendations for myasthenia gravis clinical trials.The myasthenia gravis--specific activities of daily living profile.Development of the MG-DIS: an ICF-based disability assessment instrument for myasthenia gravis.Muscle strength and fatigue in newly diagnosed patients with myasthenia gravis.Two steps forward, one step back: mycophenolate mofetil treatment for myasthenia gravis in the United States.The best of both worlds: Using patient-reported plus physician-scored measures during the evaluation of myasthenia gravis.Validity, reliability, and sensitivity to change of the myasthenia gravis activities of daily living profile in a sample of Italian myasthenic patients.Validation of the 15-item myasthenia gravis quality of life questionnaire (MG-QOL15) Persian version.Validation of the Besta Neurological Institute rating scale for myasthenia gravis.Diurnal and day-to-day variation of isometric muscle strength in myasthenia gravis.Health-related quality-of-life and treatment targets in myasthenia gravis.The MG-QOL15 Japanese version: validation and associations with clinical factors.Validation of the MG-DIS: a disability assessment for myasthenia gravis.
P2860
Q26796354-F38E38F6-FEE1-47E5-8926-F80EA9CA498FQ30357085-9D1E8A95-6DC3-42EB-8587-C45D5BCC3531Q30456336-7A3203B2-6B48-4902-83AF-F710765AF384Q37057779-82C04C73-7B10-402E-8416-98C299AF0F13Q37681359-BA904624-3061-4E8F-B7A1-97DB12E4F8AFQ38009753-0E3E91F8-7EFC-476C-8FE0-AA9FCCE3339EQ38068535-E2DBF176-C4DE-49C2-A9A4-D7A8A8B6D137Q38115565-AF2E09C8-DACA-4DE7-A45A-4BEA8821932FQ40890601-D4968264-048C-430A-987A-F4819805C3E9Q44092529-ED62EEB0-0143-486E-95C0-255ED2E45D62Q45021226-F59D9684-4035-4F8A-924D-526538C82BC5Q47303718-4483842C-C35F-4D45-9CFB-3B03D21B8E3CQ47885172-80687B2E-45C7-4BF8-94F8-57D40619ADC7Q48007236-A4E4EFD2-B235-4FCC-BA16-A985EFFC4ECEQ48039892-C97F7C09-AE82-4EFE-A030-763969B160A5Q48085548-D1C0657C-B4D3-429C-8F0D-AE994E50CB41Q48414932-5D6A2791-69C4-42D2-91E7-B29096CC8388Q50540068-4C6FDE91-6B9B-4F18-A31B-B7520C8CD30A
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
History of outcome measures for myasthenia gravis.
@ast
History of outcome measures for myasthenia gravis.
@en
type
label
History of outcome measures for myasthenia gravis.
@ast
History of outcome measures for myasthenia gravis.
@en
altLabel
History of outcome measures for myasthenia gravis
@en
prefLabel
History of outcome measures for myasthenia gravis.
@ast
History of outcome measures for myasthenia gravis.
@en
P2860
P356
P1433
P1476
History of outcome measures for myasthenia gravis.
@en
P2860
P356
10.1002/MUS.21713
P407
P577
2010-07-01T00:00:00Z